04.11.2014 Views

studiul factorilor critici in dizolvarea si eliberarea - Prezentare

studiul factorilor critici in dizolvarea si eliberarea - Prezentare

studiul factorilor critici in dizolvarea si eliberarea - Prezentare

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

STUDIUL FACTORILOR CRITICI IN<br />

DIZOLVAREA SI ELIBERAREA<br />

SUBSTANTELOR ACTIVE GREU<br />

SOLUBILE DIN FORMELE<br />

FARMACEUTICE<br />

Director de proiect:<br />

Dr. farm MIRCIOIU ION<br />

BIOPHARMACY & PHARMACOL RES S.A.


Denumirea <strong>si</strong> functia<br />

organizatiei<br />

participante <strong>in</strong><br />

cadrul proiectului<br />

CO -<br />

BIOPHARMACY &<br />

PHARMACOL RES<br />

S.A<br />

P1 -<br />

UNIVERSITATEA<br />

DE MEDICINA SI<br />

FARMACIE CAROL<br />

DAVILA<br />

BUCURESTI<br />

P2 –<br />

UNIVERSITATEA<br />

BUCURESTI<br />

Numele<br />

abreviat<br />

al<br />

organiza<br />

tiei<br />

Tipul<br />

organiz<br />

atiei<br />

2009 2010 2011 Total 36 luni<br />

De la<br />

bugetul de<br />

stat<br />

Credit de Credit de<br />

angajament angajament<br />

de la de la<br />

bugetul de bugetul de<br />

stat stat<br />

Cof<strong>in</strong>antare De la bugetul<br />

de stat<br />

Cof<strong>in</strong>antare De la Cof<strong>in</strong>antare<br />

bugetul de<br />

stat<br />

BIOPHA<br />

RMACY SACD 61 250 100 000 40 000 738 750 335 000 900 000 375 000<br />

UMF-<br />

CD<br />

UB<br />

UNI<br />

UNI<br />

48 750 65 000 95 245 491 005 700 000<br />

20 000 67 000 313 000 400 000<br />

Total 130 000 65 000 262 245 40 000 1 542 755 335 000 2 000 000 375 000<br />

<br />

Adresa web:<br />

http://umf.ro/<strong>in</strong>dex.php/ro/activitate-sti<strong>in</strong>tifica/cercetare


Obiectivul general al proiectului<br />

<br />

<strong>studiul</strong> fenomenelor de eliberare a substantelor active lipofile d<strong>in</strong> forme farmaceutice<br />

solide <strong>si</strong> semisolide <strong>in</strong> conditii cat mai apropiate de conditiile fiziologice <strong>si</strong> fundamentarea<br />

sti<strong>in</strong>tifica a unei standardizari a metodelor de dizolvare <strong>in</strong> vitro pentru medicamente greu<br />

solubile <strong>in</strong> ceea ce priveste utilizarea ten<strong>si</strong>oactivilor ca promotori de dizolvare<br />

Obiectivele specifice se refera la:<br />

<br />

<br />

<br />

<br />

<br />

<br />

dezvoltarea de medii biorelevante, cont<strong>in</strong>and agenti ten<strong>si</strong>oactivi fiziologici, care<br />

<strong>si</strong>muleaza cont<strong>in</strong>utul gastric/<strong>in</strong>test<strong>in</strong>al, pre- <strong>si</strong> post-prandial pentru <strong>studiul</strong> cedarii <strong>in</strong><br />

vitro a substantelor active lipofile d<strong>in</strong> forme farmaceutice solide<br />

elaborarea de medii de dizolvare alternative (agenti ten<strong>si</strong>oactivi de s<strong>in</strong>teza <strong>in</strong> concentratii<br />

apropiate celor fiziologice)<br />

elaborarea unor modele predictive <strong>in</strong> ceea ce priveste corelarea <strong>in</strong>tre metodele<br />

“fiziologice” <strong>si</strong> cele “alternative”<br />

elaborarea de strategii de dezvoltare <strong>si</strong> validare a metodelor de dizolvare <strong>in</strong> optimizarea<br />

formularii medicamentelor solide <strong>si</strong> semisolide.<br />

standardizarea <strong>si</strong> validarea unor metode pentru <strong>studiul</strong> cedarii substantelor active d<strong>in</strong><br />

forme solide <strong>si</strong> semisolide<br />

transferul metodelor catre producatorii de medicamente <strong>si</strong> catre Agentia Nationala a<br />

Medicamentului pr<strong>in</strong> <strong>in</strong>termediul colaborarii cu firmele producatoare <strong>si</strong> pr<strong>in</strong> <strong>in</strong>termediul<br />

unor cursuri <strong>si</strong> tra<strong>in</strong><strong>in</strong>guri d<strong>in</strong> univer<strong>si</strong>tatile partenere.


Elemente de orig<strong>in</strong>alitate:<br />

orig<strong>in</strong>alitatea abordarii efectelor ten<strong>si</strong>oactivilor la concentratii mult mai<br />

mici decat cele cercetate <strong>in</strong> mod uzual: concentratii apropiate de<br />

concentratia micelara critica, unde efectul acestora poate fi <strong>si</strong> el “critic”.<br />

<br />

evaluari bioanalitice cu echipamente de <strong>in</strong>alta performanta, studii, analiza<br />

biostatistica utilizand tehnici matematice avansate <strong>si</strong> softuri specializate<br />

(Topfit, PharmStat, Statistica, K<strong>in</strong>etica, SAS), analiza matematica <strong>si</strong><br />

modelare, analiza farmacoc<strong>in</strong>etica etc.<br />

Potentialii beneficiari ai acestui proiect sunt:<br />

<br />

producatorii de medicamente facilitarea studiilor de <strong>in</strong>troducere pe<br />

piata a noi produse, dar <strong>si</strong> pr<strong>in</strong> marirea predictibilitatii testelor de cedare<br />

<strong>in</strong> vitro utilizate <strong>in</strong> controlul calitatii.<br />

t<strong>in</strong>erii cercetatori formarea pentru activitatea de cercetare <strong>si</strong> cresterea<br />

competitivitatii.<br />

Proiectul este <strong>in</strong> esenta un proiect de cercetare cu aplicabilitate imediata<br />

pentru producatorii <strong>in</strong>dustriali de medicamente, dar rezultatele lui se<br />

transmit <strong>in</strong> f<strong>in</strong>al pana la patul bolnavului.


Conducatorul de proiect are 35 de ani.<br />

14 membri ai colectivului de realizare au sub 35 ani<br />

Responsabilul de proiect d<strong>in</strong> partea UMF “Carol<br />

Davila” este <strong>si</strong> conducator de doctorat.<br />

Unul d<strong>in</strong>tre doctoranzi a f<strong>in</strong>alizat <strong>si</strong> prezentat teza <strong>in</strong><br />

acest an , teza leagata esential de tematica proiectului<br />

5 doctoranzi au sust<strong>in</strong>ut teza <strong>in</strong> 2009 <strong>si</strong> trei <strong>in</strong> 2010 ,<br />

avand subiecte tangente cu tematica proiectului .<br />

Unul d<strong>in</strong>tre studentii implicati <strong>in</strong> acest proiect a<br />

realizat lucrarea de diploma <strong>in</strong> 2010 pe o tema<br />

legata de proiect.


Etapa 1 (1.10.2008 – 15.12.2008):<br />

<br />

<br />

Obiectiv: Studiul dizolvarii substantelor medicamentoase greu<br />

solubile, utilizand agenti ten<strong>si</strong>oactivi s<strong>in</strong>tetici<br />

Buget de stat: 130 000 lei<br />

Etapa 2 (15.12.2008 - 15.12.2009)<br />

<br />

<br />

Obiectiv: Solubilizarea substantelor medicamentoase <strong>in</strong> medii<br />

artificiale<br />

Buget de stat: 65 000 lei<br />

Etapa 3 (15.12.2009-10.12.2010)<br />

<br />

<br />

Obiectiv: Studiul <strong>in</strong>fluentei agentilor ten<strong>si</strong>oactivi s<strong>in</strong>tetici asupra<br />

parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro d<strong>in</strong> comprimate sau forme<br />

farmaceutice semisolide (<strong>in</strong>tarzierea, panta <strong>in</strong>itiala, timpul mediu de<br />

dizolvare, gradul de dizolvare) a substantelor greu solubile.<br />

Buget de stat: 262 245 lei, cof<strong>in</strong>antare 40 000 lei


Etapa 4 (10.12.2010-1.12.2011)<br />

<br />

<br />

Obiectiv: Evaluarea c<strong>in</strong>eticii de cedare <strong>in</strong>-vitro d<strong>in</strong> forme farmaceutice<br />

solide <strong>in</strong> conditii fiziologice folos<strong>in</strong>d modele experimentale.<br />

Modelarea c<strong>in</strong>eticilor de eliberare d<strong>in</strong> forme farmaceutice solide <strong>si</strong><br />

semisolide precum <strong>si</strong> a efectelor ten<strong>si</strong>oactivilor s<strong>in</strong>tetici sau fiziologici<br />

asupra acestora. Elaborarea unor metode de cedare <strong>in</strong>-vitro<br />

de rut<strong>in</strong>a, standardizate, predictive <strong>in</strong> ceea ce priveste<br />

cedarea substantei active <strong>in</strong>-vivo, alternative la metodele<br />

utilizand ten<strong>si</strong>oactivi fiziologici.<br />

Buget de stat: 1 524 755 lei , cof<strong>in</strong>antare 335 000 lei


Activitati:<br />

3.1. Studiul solubilitatii <strong>si</strong> stabilitatii substantelor active <strong>in</strong> <strong>si</strong>steme<br />

nanostructurate <strong>si</strong>muland compozitia plasmei umane<br />

3.2. Studiul dependentei parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro<br />

d<strong>in</strong> comprimate pentru substantele greu solubile, de concentratia<br />

de ten<strong>si</strong>oactivi s<strong>in</strong>tetici <strong>si</strong> de natura agentului ten<strong>si</strong>oactiv (tween,<br />

laurilsulfat de sodiu, etc) utilizat<br />

3.3. Studiul variabilitatii rezultatelor <strong>si</strong> a reprobuctibilitatii<br />

metodelor <strong>in</strong> cazul aplicarii pe comprimate d<strong>in</strong> aceea<strong>si</strong> sarja <strong>si</strong><br />

respectiv d<strong>in</strong> sarje <strong>in</strong>dustriale diferite <strong>in</strong> functie de natura <strong>si</strong><br />

concentratiile de ten<strong>si</strong>oactiv utilizate.<br />

3.4. Studiul cedarii <strong>si</strong> transportului transmembranar al<br />

substantelor active d<strong>in</strong> forme farmaceutice semisolide, utilizand<br />

diferite tipuri de membrane<br />

3.5. Disem<strong>in</strong>area rezultatelor pe scara larga, conectarea la retele de<br />

cercetare nationale <strong>si</strong> <strong>in</strong>ternationale, updatare pag<strong>in</strong>a WEB,<br />

organizare / participare la cursuri


Etapa 3-2010:<br />

Nr. Studii: 5<br />

Studiul solubilitatii Metotrexatului <strong>in</strong> surfactanti s<strong>in</strong>tetici<br />

Studiul modelarii <strong>in</strong>teractiei Metotrexat – surfactanti s<strong>in</strong>tetici<br />

Studiul reproductibilitatii <strong>si</strong> robustetii metodelor de cedare<br />

Studiul dependentei parametrilor c<strong>in</strong>etici de cedare <strong>in</strong>-vitro d<strong>in</strong><br />

comprimate pentru substantele greu solubile , de concentratia de<br />

ten<strong>si</strong>oactivi s<strong>in</strong>tetici<br />

Studiu a transferului pr<strong>in</strong> membrane semipermeabile d<strong>in</strong> forme<br />

farmaceutice semisolide, folos<strong>in</strong>d un <strong>si</strong>stem de celulele verticale<br />

de difuzie.<br />

Nr. Metode: 2<br />

Metoda de <strong>si</strong>mulare a spectrelor electronice ale medicamentelor <strong>in</strong><br />

solutii de surfactanti<br />

Metoda de modelare a corelatiei <strong>in</strong>tre proprietatile optice <strong>si</strong><br />

<strong>in</strong>teractii la nivel molecular ce <strong>in</strong>terv<strong>in</strong> <strong>in</strong>tre medicament <strong>si</strong><br />

<strong>si</strong>steme coloidale ce <strong>si</strong>muleaza plasma.


Lucrari publicate: 7<br />

Lucrari publicate <strong>in</strong> reviste cotate ISI: 3<br />

1. G Ionica, FRadulescu, D Miron, V Anuta, C Mircioiu, I Belu: Dissolution of<br />

Pentoxifyll<strong>in</strong>e from extended release formulations. Researches concern<strong>in</strong>g development of<br />

a biorelevant test, Current Health Sciences J, 35(4),286-289,2010<br />

2. I Prasacu, C Mircioiu, R Sandulovici, F Enache , Release of metoprolol from solid<br />

dosage forms. Choice and validation of theoretical model. Farmacia 57(1), 89-98, 2009<br />

3. O Purcaru, M Ionescu, C Raneti, V Anuta, I Mircioiu, I Belu Study of Nimesulide<br />

release from solid pharmaceutical formulations <strong>in</strong> Tween 80 solutions, Current Health J<br />

<br />

Vol 35 (1) 2011 –<strong>in</strong> press<br />

4. LM Miclea, L Vlaia, V Vlaia: Formulation and quality evaluation of some hydrogels<br />

conta<strong>in</strong><strong>in</strong>g piroxicam 1% and meloxicam 0.5 % , J Agroalim Proc Techn,16(1), 7-12, 2010<br />

5. D I. Hădărugăa, N G. Hădărugăb, L M Micleac, Vlaiac, C Mircioiu Bioactive<br />

compounds (hepatoprotective or anti-<strong>in</strong>flammatory xenobiotics) / cyclodextr<strong>in</strong><br />

nanoparticles: a comparative study Journal of Agroalimentary Processes and<br />

Technologies 2009, 15 (4), 478-483<br />

<br />

<br />

6. Chrenova J, Durisova M, Mircioiu C, Dedik L. Effect of gastric empty<strong>in</strong>g and enterohepatic<br />

circulation on bioequivalence assessment of ranitid<strong>in</strong>e. - Methods F<strong>in</strong>d Exp Cl<strong>in</strong><br />

Pharmacol. 2010 Jul-Aug;32(6):413-9.PMID: 20852750 [PubMed - <strong>in</strong> process]<br />

7. L - M Miclea, L Vlaia, V. Vlaia, D I. Hădărugă, C. Mircioiu Preparation and<br />

characterisation of <strong>in</strong>clu<strong>si</strong>on complexes of meloxicam and α-cyclodextr<strong>in</strong> and β-<br />

cyclodextr<strong>in</strong>. Farmacia 58 (5),583-593,2010


Brevet<br />

Mircioiu C, Cosmescu C: Gel anti<strong>in</strong>flamator ,<br />

antireumatic, anestezic, Bv 122333 B1/2009<br />

Prezentari orale: 1<br />

I Belu , O. Purcaru, M. Ionescu, C. Raneti, V. Anuta, I. Mircioiu<br />

I Belu , O. Purcaru, M. Ionescu, C. Raneti, V. Anuta, I. Mircioiu<br />

- Study Of Nimesulide Release From Solid Pharmaceutical Forms In<br />

Different Concentration Of Tween 80 - <strong>Prezentare</strong> orala <strong>in</strong> cadrul celui<br />

de-al XIV-lea Congres Naţional de Farmacie, 13-16 octombrie 2010,<br />

Targu-Mures, Romania; rezumat publicat <strong>in</strong> Acta Medica Mari<strong>si</strong>en<strong>si</strong>s<br />

(ISSN 2068-3324), Vol 56, Supplement 2, 2010, pag 88


S-au realizat obiectivele prevazute pentru acest<br />

an, chiar <strong>in</strong> conditiile unei f<strong>in</strong>antari mult<br />

reduse fata de contractul <strong>in</strong>itial.<br />

Studiile <strong>in</strong> vitro, standardizarea, validarea<br />

modelelor experimentale <strong>si</strong> teoretice, corelarile<br />

<strong>in</strong>tre metodele “fiziologice” <strong>si</strong> cele<br />

“alternative” <strong>si</strong> elaborarea unor modele<br />

predictive s-ar putea realiza <strong>in</strong> conditiile unei<br />

f<strong>in</strong>antari corespunzatoare <strong>in</strong> anul 2011, pentru<br />

a f<strong>in</strong>aliza obiectivele contractului.


Activitati:<br />

4.1. Studiul solubilizarii substantelor active, precum <strong>si</strong> al stabilitatii <strong>si</strong>stemelor<br />

rezultate <strong>in</strong> medii <strong>si</strong>muland cont<strong>in</strong>utul sucului gastric<br />

4.2. Studiul solubilizarii substantelor active, precum <strong>si</strong> al stabilitatii <strong>si</strong>stemelor<br />

rezultate <strong>in</strong> medii <strong>si</strong>muland cont<strong>in</strong>utul <strong>in</strong>test<strong>in</strong>al<br />

4.3. Studiul dependentei c<strong>in</strong>eticilor de cedare d<strong>in</strong> comprimate pentru substantele<br />

greu solubile de concentratia de acizi biliari <strong>si</strong> saruri biliare<br />

4.4. C<strong>in</strong>etici de dizolvare <strong>in</strong> volume mici de solvent, apropiate de conditiile<br />

fiziologice <strong>si</strong> estimarea c<strong>in</strong>eticii de dizolvare la volume fiziologice (100-300 ml)<br />

4.5. Studiul <strong>in</strong>fluentei unor medii <strong>si</strong>muland efectul alimentelor asupra c<strong>in</strong>eticilor<br />

de dizolvare <strong>in</strong> vitro a substantelor greu solubile d<strong>in</strong> comprimate<br />

4.6. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />

mediul gastric preprandial


Activitati (cont<strong>in</strong>uare) :<br />

4.7. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />

mediul <strong>in</strong>test<strong>in</strong>al preprandial<br />

4.8. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />

mediul gastric postprandial<br />

4.9. Efectuarea de studii de cedare <strong>in</strong> vitro d<strong>in</strong> comprimate <strong>in</strong> fluide <strong>si</strong>muland<br />

mediul <strong>in</strong>test<strong>in</strong>al postprandial<br />

4.10. Metode factoriale <strong>in</strong> analiza <strong>factorilor</strong> <strong>critici</strong> de dizolvare<br />

4.11. Studii priv<strong>in</strong>d componenta difuzionala <strong>in</strong> cedarea d<strong>in</strong> forme farmaceutice.<br />

Solutii matematice la ecuatia difuziei <strong>in</strong> conditii <strong>in</strong>itiale <strong>si</strong> de frontiera date<br />

4.12. Analiza statistica a variabilitatii rezultatelor studiilor de cedare <strong>in</strong> vitro<br />

<br />

4.13. Studii priv<strong>in</strong>d strategii de dezvoltare <strong>si</strong> validare a metodelor de dizolvare <strong>in</strong><br />

optimizarea formularii medicamentelor solide <strong>si</strong> semisolide<br />

4.14. Standardizare metode de <strong>studiul</strong> cedarii d<strong>in</strong> forme farmaceutice semisolide<br />

4.15. Elaborarea unor metrici de comparare a curbelor de dizolvare obt<strong>in</strong>ute <strong>in</strong><br />

conditii diferite<br />

4.16. Corelari <strong>in</strong>tre metodele “fiziologice” <strong>si</strong> cele “alternative” <strong>si</strong> elaborarea unor<br />

modele predictive<br />

4.17. Estimarea gradului de predictibilitate asupra comportamentului <strong>in</strong>-vivo<br />

pentru modelele elaborate<br />

4.18. Analiza beneficiu/risc <strong>in</strong> cazul folo<strong>si</strong>rii metodelor alternative <strong>in</strong> locul celor<br />

cu reactivi fiziologici<br />

4.19. Disem<strong>in</strong>are rezultate: conectarea la retele de cercetare nationale <strong>si</strong><br />

<strong>in</strong>ternationale, updatare pag<strong>in</strong>a WEB, organizare / participare la cursuri.<br />

Identificare <strong>si</strong> atribuirea drepturilor de proprietate <strong>in</strong>telectuala


Activitatile pentru 2011 , <strong>in</strong> numar de 19 sunt<br />

realizabile <strong>in</strong> conditiile f<strong>in</strong>antarii complete<br />

(<strong>in</strong>clu<strong>si</strong>v fondurile transferate pentru activitati<br />

reportate).<br />

S-ar putea reduce cheltuielile cu circa 20 - 25%<br />

S-ar putea reduce cheltuielile cu circa 20 - 25%<br />

pr<strong>in</strong> reducerea numarului de determ<strong>in</strong>ari . In<br />

aceste conditii activitatile de validare <strong>si</strong><br />

standardizare ( 4.13 – 4.18 ) vor fi mai put<strong>in</strong><br />

semnificative statistic.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!